REG-Bioventix Plc: Posting of Annual Report and Notice of AGM

BioventixAnnouncement

08/11/2022 16:15

8 November 2022
 

Bioventix plc
("Bioventix” or the "Company")

Posting of Annual Report and Notice of AGM

Bioventix plc (AIM: BVXP), a UK company specialising in the development and
commercial supply of high-affinity monoclonal antibodies for applications in
clinical diagnostics, announces that it has today posted its Annual Report for
the year ended 30 June 2022 together with a Notice of Annual General Meeting
("AGM") and Form of Proxy to shareholders that have elected to receive
documentation in hard copy format. Both documents will also be available from
the Company's website at www.bioventix.com under the Investors section.

The Company's AGM will be held at Farnham Castle, Farnham, Surrey, GU9 0AG on
Thursday 8 December 2022 at 2.00pm.

For further information please contact:

 Bioventix plc Peter Harrison                   Chief Executive Officer  Tel: 01252 728 001  
                                                                                             
 finnCap Ltd Geoff Nash/Simon Hicks Alice Lane  Corporate Finance ECM    Tel: 020 7220 0500  

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce
a suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares are
traded on AIM under the symbol BVXP.



Copyright (c) 2022 PR Newswire Association,LLC. All Rights Reserved